• This session will focus on the impact of perimenopause in those who have underlying mental health conditions such as bipolar disorder, schizophrenia, schizoaffective disorder, treatment resistant or recurrent depression. This cohort of patients are often on drugs that have interactions with hormone therapy, and we will review the options available.

Genitourinary syndrome of menopause 

• This session will help with understanding pathophysiology, prevalence, symptoms and signs, patient resources and treatment options in relation to GSM. Helping menopausal women navigate urogenital symptoms and providing them with the right information before the burning begins!

Epilepsy, the menopause transition and HRT 

• Women with epilepsy may experience changes in seizure control during the menopause transition, particularly if seizures have previously shown a catamenial pattern. Estrogen is generally proconvulsant and progesterone is anticonvulsant, providing a biological rationale for worsening in some women during perimenopause, when estrogen levels fluctuate or rise while luteal progesterone falls. Epilepsy is not a contraindication to HRT, but the lowest effective dose of estrogen is recommended, and seizure control should be monitored after starting or changing HRT. Enzyme-inducing antiseizure medications may reduce HRT efficacy, while estrogen exposure may lower lamotrigine concentrations. Close collaboration between menopause and epilepsy clinicians is appropriate when seizure control changes or antiseizure medication adjustment is required.

The BMS Masterclass carries 3 CPD credits.

Please note this webinar will not be recorded.

We are unable to issue refunds for this event.